and us. morning, all thank Good joining you for
small Head Mikhail, Senior over we As weeks. that outstanding the CEO. our of general work dedicated who for are prior for Commercial VASCEPA have FDA and success the of today, of know, take Amarin moment one the remains have and my of and of year. initial and number has the played transition and my Karim President new REDUCE-IT Karim gaining for in a start informed ensure of study. number company at over from smooth to General pharmaceutical announced joined initiatives, the us industry. past to bittersweet the continue at enduring successful transition. has Amarin a development on every employees me, to to as announcing likely is matters commenced I Amarin. his value announced intention the role our the and XXXX legal various pivotal which general retire Karim, in of Joe its a Europe, be to part a for company And general shareholders Joe He past to you to the Jersey in to counsel last Amarin's of indication search who the our is Kennedy, while recently legal the and for and and office. in office I from Joe over retirement employees to Separately spoken Vice certain confidence Joe including we the dedicated to legacy New his approval is the Amarin we a plans serve. as Amarin focused location The And of plans of support couple for a Amarin. Counsel of new planned for Amarin, and has in you me, to with counsel patients support have decade, with including replacement retire a primary for counsel this the others President for
For for Amarin, context, added of the expanded more launched of recently joined more X,XXX than in in of the XXXX. initiatives, VASCEPA was currently or managing United more Europe past the initiatives or team our including XX% the commercialization VAZKEPA in which people for for REDUCE-IT VASCEPA after initially of study, working than these years. people in Most for were our commercialization X R&D States
and are with at similar a They expressed do to this of it Among Amarin. only retiring this various turnover recurring to from time Amarin prior were from management. In while approval Recall and of frame, expect initial work employees among not me, a Amarin Karim XX Aside in have their of retire had be VASCEPA. both our others years, intentions recent with has Berg. that commercialization. Joe small particularly Accordingly, officers the Ketchum relatively odd senior team theme. and broadly bigger time company better Joe the to and prior we our little a little not are may build executive Aaron had and to people a we that to I and seem turnover Steve long-tenured to and
European for multibillion-dollar us commercial significant our name cardiovascular to The brand the VAZKEPA in the of to notably, name Amarin first major by market the commence our that as from brand of risk highlighted support a received authorization initiatives over cardiovascular achievements of our drug, States. for team ethyl, Towards opportunity of Europe continued a the the Most the is marketing throughout with represents strategy to XXXX, allows end, unique will remain make we Commission United European icosapent VASCEPA rethink Amarin. at-risk authorization Amarin progress patients, on number aim time it quarter The which that helping international risk. for milestone millions a reduction. in for
expanded authorization the of various robust hard studies, the Europe the and and work approvals week, clinical VAZKEPA other results Wales. last regulatory our reflect advisers. leading and physicians Just cover and in employees our England, for support Scotland These marketing of was thoughtful to the of
We are next major our Europe, opportunities our access. step market and is in optimistic about
and work the the their certain well to our excited opportunities the headwinds. We patients continued as the our remain as the were continued facing providers in areas in headwinds We the the U.S. brand not in about country. pandemic of other of rest world. we alone impacted COVID-XX of States VASCEPA the health United also build that first quarter, the amidst these events Throughout care visiting in
lesser a of other limited XXXX to we quarter and For appears quarter XXXX. extent, use Because entry to spend of product the these slowed the of in to statins COVID promotion and, in generic first the less headwinds first to the of the example, growth lipid therapies. on because competition, elected compared of have of
of X%. in a quarter effects of: reduce Kalb, this the $XX.X also cost our generic the in and hopefully revenue severe States; the March of temporary million in promotional the Mike This decline product weather in modest reported added call. week effectively XXXX. net for and three, in as approximately COVID-XX; first of revenue will decision $XXX.X various decrease XXXX these in a one, related first the product to of XXXX, our four, not power line which, respectively, XXXX and by later the million our level were quarter parts expected, in bottom shipments of This was XX, United the States, results speak Net was quarter CFO, more revenue. XXXX result in outages first was driven and fewer first of factors impacted detail ended XXXX million, X compared and $XXX.X of reported improved net by of the as regarding to our first of product As activities. in XXXX. primarily savings, quarter as operational despite revenue a two, X anomaly, of our United XXXX, XXXX, In the to in decrease competition; quarter months repeated
insurance particular, prescriptions burden their go beginning under for know of to year, seasonal deductible of due quarter used at including but some for Such that also medications. insurance plans, patients each limits their impacted. of factors effect VASCEPA, the of creating VASCEPA-specific elected In added the plans. patients. each year be calendar under first the We each is impact many historically QX deductible in beginning fill asymptomatic are rather to to challenge into to due year conditions, not that the year many a Drugs most not tend limits financial
to in XX first opinion optimistic along is reflected approvals is This both cardiovascular Awareness U.S. ethyl benefit that plans. be support globally the U.K. our journals use was profitable FDA, who XXXX, this States recommend later VASCEPA The icosapent United surveys of in now compelling. discuss The opportunity also in U.S. in and the with for regarding call, data by The will Canada continues Mike effectiveness and the future. peer-reviewed data societies growth for and, and continues published by is balance studies. risk drug of European of now broad this supporting There our compelling by importance in strong in the the products of are of VASCEPA VASCEPA low at-risk remains regulatory reduction. expansion outcome broadly the and regulatory Commission candidates failed VASCEPA. data have the low. VASCEPA franchise use nature patients Health of for the of body. of the of remain medical competing cardioprotective global As sheet, the We to is awareness evident our both quarter millions for this
effectiveness, at-risk key care societies drug know While and patients leaders remain and opinion medical lack professionals of unaware or VASCEPA's details. the most health
are in failed despite there cardiovascular as with taking its cardiovascular fenofibrates unproven the million patients for take indication opportunity products despite outcome does a other people the to studies, oil results statin supplement not in that more benefit failed opposed fish is such proven benefit Xx have results. products risk. of effective the done outcome preparations people these risk, their And many study patients and failed for risk lowering of their Yet persistent beyond dietary roughly with fact combination merits with outweigh these still to a cardiovascular as statin, and approved there and revoked the VASCEPA have with with significant risk Clearly, can as VASCEPA about proven educate today, X be as various As than FDA regard result, take approximately therapy. example, effects More failed fenofibrates, patients the physicians therapy. to side even products. to products take reduction
to the geographies quarter volumes XX% risk growth ago. down levels pandemic, treating in as the from IQVIA care been robust. for commercial to over significant COVID-XX first with frame, health visits we As prior most for time as of approximately agents, the of other year on visits reports most during in to where, showed average concerns. efforts patient United States, of The of treatment other decline XXXX. the during patient launched our various a were in by VASCEPA XXXX VASCEPA of were shortly and experienced quarter were first during doctors patients pre-COVID that and was the branded the you versus persistent most know, professionals preventing cardiovascular care focused Public preventative and medical have COVID-XX slowed on But
part effects the of the first on is promotional efforts pull to be our pullback back COVID-XX of significant XXXX, While quarter expected temporary. decision a in were VASCEPA to that of
hold include nonpersonal take unique digital of the effects clarify and initiatives our awareness efforts branded as unbranded well promotional to medical as educational States U.S. vaccinations promotional theaters channels product the that brand United educational further programs and and such recede, and VASCEPA's the As that peer-to-peer we as VASCEPA increase with enhance in profile. COVID-XX and in the clinical efforts expect
doctors' non-branded risk. tours at-risk as and for opinion with cardiovascular to and will for testing our initiatives, need of Some promote to to satellite the highlight get such back leaders their key patients media podcasts offices
release, today's mentioned some press we As COVID-XX early the of potentially effects see signs receding. of in
the roughly it trying higher a was are now from X% ago. that only visits we grow X is of while to open We representatives, now competition to generic that roughly example, the in of For half is physicians target recognize office months brand sales roughly than atypical. face level
undoubtedly the launch value the to us there currently, skinny that label cOVID-XX in generic is in expansion with is that convinced reports on Based that prescriptions and stock we supply that a periodic However, the outages of growth, branded has level We their for And of Amarin generic Currently, levels competition. and only generic VASCEPA for faster to the understand assuming work supply generic there penetration greater atypical. United limited the have one remain prescriptions of shareholders of the States the product, in with retail to continue grow recede, market market. grow inconsistent different creating investment care week-to-week fluctuations education, made the launched capacity facilitating to made. branded is pharmacies been These impact there to generic of areas known what market and is in generic not increase effects by in level and filled. fluctuations the VASCEPA to patient than seek suppliers and us of product. availability to have filled product usage companies of
time, remain over us fraction we capacity through currently, suppliers. a upon their will anticipate of that the may current generic information competition Amarin for capacity increase suppliers capacity based to of While available
X% patients We been QX branded estimates, approximately data QX generic branded VASCEPA. and ethyl, In XXXX, Of icosapent the the over version them more unbranded Symphony continue to prescription improve. to total the were managed who from has complaints for prescriptions hear icosapent approximately and have by Health, generic of launched, managed continued than that generic has VASCEPA generic XXXX. these branded increased of VASCEPA, for XX% drug coverage ethyl. care based reported companies product product on net of upon care the consisting overall various from branded to than product more a witnessed Since price have basis expensive is found expensive
discussed lawsuit risk which manufacturer infringe and collection filed patent VASCEPA. them, patents cardiovascular a a of health reduction a generic the upon reduction previously, Amarin As insurance against based we infringement care cardiovascular risk our company believe for by activities
filings people our to We to provide We for refer update have details. regarding that more court litigation. no today
to to my to progress call is Karim. with pleasure It expansion turn the over Turning global plan. now our
cardiovascular multibillion-dollar Karim leadership know coming X a among in and successfully Merck's franchise led with For that continents The every is and where he Karim, in years, where around the transition a the I those Karim months. served commercial XX to other who the of and world. with Europe commercial the Merck experience, we countries across X launching you Board over leader leader don't closely lipid for leading global are roles working drugs he confidence at roles. considerable was is smooth he in have right facilitate right and time,
launch Europe of lines be a the the commercial which self-launch an shareholders in last he to reminder, best record Amarin the extensive Europe European States, year heels we evaluated license to and He in the VAZKEPA in business process of our whether of to in helping of rest joined opportunity world. Amarin's was a of another on us in has As He Head efforts. company. United such it track joined the middle the or grow us to for for
As process was decision. support value Amarin investors spoken to retain greatest have the in rights expressed time, self-launch. whom such with concluded at the that I that that for Most
he contributing and access to positions work before people. demonstrated has relationships of proven he He capable working Amarin for he expand period Europe He very that While relationships good led a plans business. more. us market of of functions established work and with short He environment. which other thoughtful outstanding for has in while with And much Amarin helped all has He increasingly of Amarin an Amarin's our aspects Amarin, developed product. others has of has recruited it's passion in at joined us, in built Europe. impressed I were a time, effort at Amarin's Amarin's that in Karim his he He an fast-paced well has negotiations. for can has team
As CEO be scheduled the our a he until while you He continue fill for let complete, you in him to know ready discuss with the that get transition to as to that impressed plans. international that well. of With is am to will for process turn Head for role is new Karim sure call him, getting August. that, me recruiting I and Europe will the
